Enzolytics, Inc. Enters Into Collaboration Agreement With Manufacturer Elimus Ltd.

July 29, 2024 9:50 AM

Enzolytics, Inc. (OTC PINK:ENZC) ("enzolytics.com")(the "Company") announced today that it has entered into a 4 year Collaboration Agreement with Elimus, Ltd ("Elimus"), a Bulgarian company located in Sofia, for the manufacturing, development and marketing of new and existing nutraceutical products of the two entities. The product license will be for the territory of North America (the United States, Canada and Mexico). The Company will utilize...

Read more

Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

July 29, 2024 9:20 AM

Utilization of the Company's proprietary Web App showed improved self-selection utilizing an embedded validated diagnostic questionnaire compared to a live interview furthering the Company's efforts to potentially create a first-ever Rx-to-OTC switch in the ED categoryNEW YORK, NY / ACCESSWIRE / July 29, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication...

Read more

Lifeloc Technologies, Inc. Appoints Adam Kashenberg to its Board of Directors

July 26, 2024 11:25 AM

Lifeloc Technologies, Inc. (OTC PINK:LCTC) (the "Company"), a global leader in the development and manufacturing of breath alcohol testing devices, has announced the appointment of Adam Kashenberg, president and CEO of Colorado Biolabs, Inc., to its Board of Directors (the "Board"), effective July 23, 2024."We are pleased to welcome Adam to Lifeloc's board," said Vern Kornelsen, Lifeloc's Chief Financial Officer and Board chair. "Adam is an...

Read more

Enzolytics Inc. Supports Sagaliam Acquisition Corp Response to Competitors False and Misleading Press Release

July 26, 2024 11:00 AM

Enzolytics, Inc. (OTC PINK:ENZC) (enzolytics.com) (the "Company") stated today that the Company will whole heartedly support any and all efforts by Sagaliam Acquisition Corp ("SAGA") in its campaign to stop another attempt by NIKA Pharmaceutical and its CEO, Dimtar Savov, falsely claiming rights to patents issued to Harry H. Zhabilov and the Zhabilov Trust for the Immunotherapy treatment of HIV/AIDS. Mr. Savov has, since defaulting on licensing...

Read more

SOHM, Inc., Announce a New Collaboration and Joins Forces with Stanford University

July 25, 2024 9:30 AM

SOHM, Inc. (OTC PINK:SHMN) (the "Company"), a pharmaceutical and upstart biotechnologycompany that manufactures and markets generic drugs covering numerous treatment categories, announced that it has signed a new agreement with Standford University.In an exciting development, SOHM announces a groundbreaking collaboration of ABBIE Technology with Stanford University, one of the world's leading research institutions. This strategic partnership...

Read more

Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement

July 24, 2024 6:30 AM

Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, and Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS) (Pieris) today announced they have entered into a definitive merger agreement to combine the companies in an...

Read more

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board

July 22, 2024 8:30 AM

BRIDGEWATER, NJ / ACCESSWIRE / July 22, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, today announced the appointment of David Jones, Professor of Liver Immunology at Newcastle University in England, to its Scientific Advisory Board (SAB).Prof. Jones has earned an international reputation for his work...

Read more

BioInvent to Present Pipeline Progress on BI-1910 and BT-001 at ESMO

July 22, 2024 2:20 AM

LUND, SWEDEN / ACCESSWIRE / July 22, 2024 / BioInvent International (STO:BINV)Two posters to be presented on early clinical projects from BioInvent's robust pipeline totaling six clinical programs:Progress with the Phase 1 trial studying BI-1910 as single agent in solid tumorsInitial clinical data from the BT-001 Phase 1 study evaluating the candidate both as single agent and in combination with KEYTRUDA® (pembrolizumab) in patients with solid...

Read more

Biomind Labs To Redefine Obesity Treatment With Its New BMND06 Candidate Targeting Neurological Pathways

July 18, 2024 8:30 AM

Biomind Labs Inc. ("Biomind" or the "Company") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI), a leading biotech company dedicated to developing the next-generation of pharmaceuticals targeting the root causes of neurological disorders, announced the decision to advance a new Phase II clinical trial. This decision follows new and unexpected findings from a pre-clinical study of its proprietary compound 3,4,5-trimethoxyphenethylamine-based BMND06.The...

Read more

Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne

July 17, 2024 9:00 AM

Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced that it has successfully enrolled 50% of patients in its pivotal Phase 3 Spongilla Treatment for Acne Research (STAR-1) study of DMT310, a novel, once-weekly, topical product candidate for the treatment of moderate-to-severe acne. The STAR-1...

Read more

Briefly Bio Launches with $1.2m Funding to Help Scientists Reproduce Complex Experiments

July 17, 2024 8:30 AM

LONDON, UK / ACCESSWIRE / July 17, 2024 / Science is in a reproducibility crisis. In preclinical research, it's estimated that over 50% of efforts to reproduce experiments fail, costing the industry over $50bn each year. Solving this problem, techbio startup Briefly Bio has launched with software that makes lab work more reproducible by helping scientists capture and share their work clearly and consistently.With this launch, Briefly Bio has...

Read more

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

July 17, 2024 8:30 AM

BRIDGEWATER, NJ / ACCESSWIRE / July 17, 2024 / Tharimmune, Inc. (Nasdaq:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation and immunology, announces the appointment of David H. Clarke as a Strategic Advisor to the Company's executive management team."Tharimmune is pleased to have David join in an advisory capacity," stated Randy Milby, CEO of Tharimmune....

Read more

AbTherx Appoints Pallavi Tawde, PhD, as Head of Preclinical R&D Strategy

July 17, 2024 6:00 AM

AbTherx, a biotechnology company with innovative technologies that enable and accelerate therapeutic antibody discovery and development, today announced the appointment of Pallavi Tawde, PhD, to the newly created position of Head of Preclinical R&D Strategy. Dr. Tawde will oversee AbTherx's expansion of antibody discovery efforts including the development of single B cell technologies for targeting cell surface proteins and preclinical...

Read more

BioInvent Announces New Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BI-1607 in Combination with KEYTRUDA (Pembrolizumab) and Ipilimumab

July 17, 2024 2:30 AM

LUND, SE / ACCESSWIRE / July 17, 2024 / BioInvent International (STO:BINV)Agreement to support expansion of BI-1607 program with new Phase 2 triplet combination study in metastatic melanomaThe study will evaluate anti-FcγRIIB antibody BI-1607 with low-dose anti-CTLA-4, ipilimumab, plus KEYTRUDA®Phase 1 data previously demonstrated BI-1607 is safe and well tolerated and achieves full receptor occupancy during the treatment interval at several...

Read more

Elixirgen Scientific Launches Advanced hiPSC-Derived Disease Panel for Alzheimer’s Disease

July 16, 2024 1:00 PM

Maryland-based biotechnology leader, Elixirgen Scientific, Inc., launches Alzheimer's Disease Panel, strengthening their commitment to quality and innovation in disease research and drug discovery.BALTIMORE, MD / ACCESSWIRE / July 16, 2024 / Elixirgen Scientific, Inc., a biotechnology leader focused on advancing drug discovery and revolutionizing cell therapy through hiPSC technology, announced today the launch of its new Alzheimer's Disease...

Read more

Petros Pharmaceuticals’ STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance

July 16, 2024 9:00 AM

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, announces results of the first of a series of pivotal studies aimed at facilitating FDA-approved OTC access of STENDRA® (avanafil) for consumers. The pivotal self-selection study showed that consumers who used the Company's proprietary Web App Technology,...

Read more

Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104

July 16, 2024 8:30 AM

BRIDGEWATER, NJ / ACCESSWIRE / July 16, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or the "Company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates in inflammation & immunology, announces the launch of its new website at www.tharimmune.com. This redesigned online platform provides patients, healthcare professionals and stakeholders with comprehensive information about Tharimmune's cutting-edge...

Read more

Announcement from Biovica International AB's Extra General Meeting

July 15, 2024 9:45 AM

UPPSALA, SWEDEN / ACCESSWIRE / July 15, 2024 / The extra general meeting of Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) ("Biovica" or the "Company") was held today on 15 July 2024 and the following resolutions were passed by the meeting.SHARE SAVINGS PROGRAM 2024/2027:1 FOR SENIOR EXECUTIVES AND KEY PERSONNEL WITHIN THE COMPANY AND THE GROUP IN SWEDEN AND DENMARKThe extra general meeting resolved, in accordance with the board of...

Read more

Moolec Signs an Offtake Agreement With Major Global CPG Company to Hit the US Market in 2025

July 15, 2024 6:00 AM

LUXEMBOURG / ACCESSWIRE / July 15, 2024 / Moolec Science SA (NASDAQ:MLEC) ("the Company"), a Molecular Farming ingredient company, announced today the signing of an offtake agreement with one of the largest global consumer packaged goods and pet food companies for the use of Moolec's patented science-based GLA Safflower Oil product, GLASO™ (the "Agreement"). This initial offtake agreement has a term of three years and establishes commercial...

Read more

Alligator Bioscience AB Reports Financial Results for H1 2024 and Q2 2024 and Provides a Business Update

July 11, 2024 2:20 AM

LUND, SWEDEN / ACCESSWIRE / July 11, 2024 / Alligator Bioscience (STO:ATORX)Substantial overall survival benefit and unprecedented Duration of Response reported in 18-month analysis from mitazalimab OPTIMIZE-1 Phase 2 study in 1st line pancreatic cancerPositive Phase 2 mitazalimab data published in The Lancet OncologyJohan Giléus appointed as new Chief Financial OfficerOrion exercises development option in research collaboration and license...

Read more